Crinetics Pharmaceuticals Files 8-K
Ticker: CRNX · Form: 8-K · Filed: May 22, 2024 · CIK: 1658247
| Field | Detail |
|---|---|
| Company | Crinetics Pharmaceuticals, Inc. (CRNX) |
| Form Type | 8-K |
| Filed Date | May 22, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, sec-filing
Related Tickers: CRNX
TL;DR
CRNX filed an 8-K, standard disclosure stuff.
AI Summary
On May 22, 2024, Crinetics Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No specific financial figures or material events beyond the filing itself are detailed in the provided text.
Why It Matters
This filing indicates Crinetics Pharmaceuticals is making required disclosures to the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a routine disclosure and does not contain information about significant risks or material events.
Key Players & Entities
- Crinetics Pharmaceuticals, Inc. (company) — Registrant
- May 22, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-38583 (identifier) — SEC File Number
- 26-3744114 (identifier) — IRS Employer Identification No.
- 6055 Lusk Boulevard San Diego, California 92121 (address) — Principal Executive Offices
- (858) 450-6464 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing for Crinetics Pharmaceuticals, Inc.?
The filing is primarily for Regulation FD disclosures and to report financial statements and exhibits.
On what date was this 8-K report filed or effective?
The date of the report, and the date of the earliest event reported, is May 22, 2024.
In which U.S. state is Crinetics Pharmaceuticals, Inc. incorporated?
Crinetics Pharmaceuticals, Inc. is incorporated in Delaware.
What is the SEC file number for Crinetics Pharmaceuticals, Inc.?
The SEC file number is 001-38583.
Where are the principal executive offices of Crinetics Pharmaceuticals, Inc. located?
The principal executive offices are located at 6055 Lusk Boulevard, San Diego, California 92121.
Filing Stats: 763 words · 3 min read · ~3 pages · Grade level 11.8 · Accepted 2024-05-22 08:23:34
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share CRNX Nasdaq Global Select
Filing Documents
- d815433d8k.htm (8-K) — 25KB
- d815433dex991.htm (EX-99.1) — 7KB
- g815433dsp1.jpg (GRAPHIC) — 9KB
- 0001193125-24-144484.txt ( ) — 164KB
- crnx-20240522.xsd (EX-101.SCH) — 3KB
- crnx-20240522_lab.xml (EX-101.LAB) — 17KB
- crnx-20240522_pre.xml (EX-101.PRE) — 11KB
- d815433d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this report are forward-looking statements. These forward-looking statements speak only as of the date of this report and are subject to a number of known and unknown risks, uncertainties and assumptions, including, without limitation, the risks and uncertainties described in the Company's periodic filings with the Securities and Exchange Commission ("SEC"). The events and circumstances reflected in the Company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading "Risk Factors" in Crinetics' periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2023 and quarterly report on Form 10-Q for the quarter ended March 31, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Item9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated May 22, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Crinetics Pharmaceuticals, Inc. Date: May 22, 2024 By: /s/ R. Scott Struthers, Ph.D. R. Scott Struthers, Ph.D. President and Chief Executive Officer (Principal Executive Officer)